drugset

drugset / Trial / NCT00987038

A Midazolam Drug Interaction Study With PF-04171327

NCT00987038 ↗

Phase 1 Completed 12 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effects of multiple doses of PF-04171327 on the blood levels (pharmacokinetics) of midazolam

Timeline

Start: 2009-09
Primary completion: 2009-12
Completion: 2009-12

Publications

Ripp SL, Mukherjee A, Eng H, Stock T, Fleishaker D, Checchio T, Tammara B. In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor. Clin Pharmacol Drug Dev. 2018 Mar;7(3):244-255. doi: 10.1002/cpdd.411. Epub 2017 Nov 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Midazolam	Small molecule	2 mg	Oral
Subject	fosdagrocorat	Small molecule	25 mg	Oral

Indications

No indication recorded.